Lung Cancer – Page 4 – Medical News Asia

Frontline atezolizumab plus chemotherapy improves PFS in NSCLC

25 September 2018/0 Comments/in WCLC 2018, Lung Cancer, Oncology, Chemotherapy, Immunotherapy/by scienterrific

An interim analysis of the Phase III IMpower132 study showed that atezolizumab (Tecentriq®, Roche/Genentech) plus platinum-based chemotherapy (cisplatin or carboplatin) with pemetrexed improves the median progression-free survival (PFS) in treatment-naïve patients with non-squamous non-small cell lung cancer (NSCLC). The median PFS for atezolizumab plus pemetrexed and a platinum salt was 7.6 months vs 5.2 months with chemotherapy alone (HR=0.60, 95% CI: 0.49-0.72; p<0.0001).

First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC

24 September 2018/0 Comments/in Lung Cancer, Oncology, Targeted Therapies/by Stijn van den Borne, MSc

First-line osimertinib was associated with a clinically meaningful progression-free survival (PFS) improvement when compared to a standard-of-care (SOC) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) in a sub-analysis of Asian patients who participated in the FLAURA trial (NCT02296125).

Capmatinib plus gefitinib promising in MET-dysregulated NSCLC

11 September 2018/0 Comments/in China, Lung Cancer, Oncology, Targeted Therapies/by scienterrific

The combination capmatinib (INC280, Novartis) plus gefitinib (Iressa®, AstraZeneca) showed promising, early phase efficacy in patients with mesenchymal-epithelial transition factor (MET)-dysregulated and epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

Plasma TMB predicts response to atezolizumab in NSCLC patients

31 August 2018/0 Comments/in Lung Cancer, Oncology, Chemotherapy, Immunotherapy, Pathology, Translational Research/by scienterrific

A high tumour mutational burden in the plasma (bTMB) is a clinically actionable biomarker for atezolizumab (Tencentriq®, Roche) treatment in patients who failed 1st-line platinum-based therapy for advanced non-small cell lung cancer (NSCLC).

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

22 August 2018/0 Comments/in Breast Cancer, Medical News Asia, Genitourinary Cancer, Lung Cancer, Melanoma & Skin Cancer, Oncology, Immunotherapy, Translational Research/by scienterrific

Biosceptre has announced the initiation of its Phase 1 clinical study with the peptide vaccine BIL06v. BIL06v is a peptide-protein conjugate that recruits the patient’s immune system to make antibodies specifically targeted at nfP2X7-expressing cancer cells resulting in tumour cell death.

Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)

21 August 2018/0 Comments/in US FDA Onc\Haem Approvals, Lung Cancer, Oncology, Immunotherapy/by scienterrific

On the 16th of August 2018, the FDA granted accelerated approval to nivolumab (Opdivo®, Bristol-Myers Squibb) for use in patients with metastatic small cell lung cancer (SCLC) who progressed after two lines of therapy, including one line of platinum-based chemotherapy.

Pembrolizumab plus pemetrexed-platinum FDA approved for first-line treatment of metastatic non-squamous NSCLC

21 August 2018/2 Comments/in US FDA Onc\Haem Approvals, Lung Cancer, Oncology, Immunotherapy/by scienterrific

On 20th of August 2018, the FDA granted regular approval for pembrolizumab (Keytruda®, Merck) plus pemetrexed and a platinum salt in the first-line treatment of patients with metastatic, non-squamous non-small cell lung cancer (NSCLC), not harbouring any EGFR or ALK genomic tumour aberrations.

Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China

13 August 2018/0 Comments/in China, Medical News Asia, Lung Cancer, Oncology, Targeted Therapies/by scienterrific

HONG KONG, CHINA – 13 August 2018 – Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), announced that its innovative in-house developed oncology drug pirotinib has commenced into Phase II Clinical testing in China following the completion of a Phase I clinical trial in three renowned cancer research centres in the United States.

Osimertinib in patients with T790M-positive advanced non-small cell lung cancer and brain metastases (AURA3)

30 July 2018/0 Comments/in Lung Cancer, Oncology, Chemotherapy, Targeted Therapies, Translational Research/by scienterrific

Osimertinib is active in the second-line treatment of patients with T790M-positive advanced non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases, as reported by the investigators of the Phase III AURA3 study.

ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised

25 June 2018/5 Comments/in ASCO 2018 Annual Meeting, Lung Cancer, Oncology, Chemotherapy, Immunotherapy, Targeted Therapies/by Anne John Michael

Non-small cell lung cancer (NSCLC): a key feature of the American Society of Clinical Oncology (ASCO) 2018 annual meeting. This year, encouraging results with single-agent immunotherapy (I-O) and combinations of I-O with chemotherapy (CTx), including the CheckMate 227 with nivolumab (NIVO), IMpower131 and IMpower150 studies with atezolizumab (ATEZO), and KEYNOTE-042 and KEYNOTE-407 studies with pembrolizumab (PEMBRO). Furthermore, important Asian data on treatments for epidermal growth-factor recptor (EGFR) mutation-positive (mu+) NSCLC (ARCHER 1050, NEJ009, NEJ026, and JO25567).